Curis to Present at the Cowen and Company 33rd Annual Health Care Conference

Curis to Present at the Cowen and Company 33rd Annual Health Care Conference

LEXINGTON, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS),
an oncology-focused company seeking to develop next generation targeted drug
candidates for cancer treatment, today announced that the Company will be
presenting at the Cowen and Company 33^rd Annual Health Care Conference at
4:10 p.m. EST on March 4, 2013, in Boston.

Dan Passeri, Chief Executive Officer, will provide an overview of Erivedge®
(vismodegib), a hedgehog pathway inhibitor under collaboration with Genentech
that is the first FDA-approved medicine for people with advanced forms of
basal cell carcinoma.Mr. Passeri will also provide an overview of Curis'
other cancer programs including CUDC-427, CUDC-101, CUDC-907 and Debio 0932,
as well as discuss other corporate activities.

A corresponding webcast of the presentation can be accessed by visiting:

http://wsw.com/webcast/cowen10/cris/

The presentation will be archived shortly after the live event and available
for 30 days following the conference. In addition, it will be available for 30
days on the Investor Relations section of the Curis website at www.curis.com.

About Curis, Inc.

Curis is an oncology-focused drug development company seeking to develop and
commercialize next generation targeted small molecule drug candidates for
cancer treatment. Erivedge® is the first and only FDA-approved medicine for
the treatment of advanced basal cell carcinoma and is being commercialized and
developed by Roche and Genentech, a member of the Roche Group, under a
collaboration agreement between Curis and Genentech. Curis is also leveraging
its experience in targeting signaling pathways to develop proprietary targeted
cancer programs, including CUDC-427, a small molecule antagonist of IAP
proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information,
visit Curis' website at www.curis.com.

The Curis, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=11347

CONTACT: For More Information:
         Michael P. Gray
         Chief Financial Officer
         Curis, Inc.
         617-503-6632
         mgray@curis.com

Curis, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.